검색어: leukapheresis (영어 - 크로아티아어)

the leukapheresis process
postupak leukafereze

adverse reactions associated with leukapheresis
nuspojave povezane s leukaferezom

filgrastim dosing should be maintained until the last leukapheresis.
doziranje filgrastima treba održavati do posljednje leukafereze.

peripheral stem cell donation is done through a process called leukapheresis .
periferne matične stanice uzimaju se postupkom leukafereze .

chest discomfort decrease of platelets in the blood due to the leukapheresis procedure
bol u prsima smanjenje trombocita u krvi zbog postupka leukafereze

for patients who have not had extensive chemotherapy, one leukapheresis is often sufficient.
u bolesnika koji nisu primali opsežnu kemoterapiju često je dovoljna jedna leukafereza.

citrate is generally the preferred anticoagulant used during leukapheresis and can result in hypocalcaemia.
citrat je uobičajeni antikoagulans koji se primjenjuje tijekom leukafereze i koji može dovesti do hipokalcemije.

if more than one leukapheresis is required, particular attention should be paid to donors with platelets
treba li obaviti više od jedne leukafereze, nužan je poseban oprez u davatelja s trombocitima

each dose of provenge requires a standard leukapheresis procedure approximately 3 days prior to the infusion.
svaka doza lijeka provenge zahtijeva provođenje standardnog postupka leukafereze oko 3 dana prije infuzije.

visit 1 – blood cell collection (leukapheresis) visit 2 – provenge infusion
dolazak - prikupljanje krvnih stanica (leukafereza) dolazak – infuzija lijeka provenge

each provenge infusion comprises the maximum number of cells that can be manufactured from a single leukapheresis procedure.
svaka infuzija lijeka provenge sadrži najveći broj stanica koje mogu biti dobivene jednim postupkom leukafereze.

in such cases, the patient may need to undergo an additional leukapheresis procedure if the treatment is to be continued.
u takvim slučajevima, bolesnik će možda morati ponovno proći postupak leukafereze ukoliko se liječenje želi nastaviti.

therefore patient leukapheresis material and provenge may carry the risk of transmitting infectious diseases to healthcare professionals handling the product.
stoga kod uzorka dobivenog leukaferezom i lijeka provenge postoji rizik od prenošenja zaraznih bolesti na zdravstvene djelatnike koji rukuju lijekom.

in clinical studies, about one quarter of the patients required more than 3 leukapheresis procedures in order to receive 3 infusions of provenge.
u kliničkim ispitivanjima, kod približno jedne četvrtine bolesnika bila su potrebna više od 3 postupka leukafereze kako bi se primijenile 3 infuzije lijeka provenge.

additionally, there have been reports of thrombocytopenia received in spontaneous post-marketing reporting that have been temporally associated with leukapheresis.
također postoje izvješća o trombocitopeniji zaprimljena tijekom spontanog postmarketinškog izvješćivanja, a koja su privremeno povezana s leukaferezom.

accordingly, healthcare professionals should employ appropriate precautions when handling leukapheresis material or provenge (see section 4.4).
prema tome, zdravstveni djelatnici se trebaju pridržavati odgovarajućih mjera opreza prilikom rukovanja uzorkom dobivenim leukaferezom ili lijekom provenge (vidjeti dio 4.4).

leukapheresis should be started at day 5 and continued until day 6 if needed in order to collect 4 x 106 cd34+ cells/kg recipient bodyweight.
leukaferezu treba početi 5. dan i nastaviti do 6. dana bude li potrebno da se prikupi 4 x 106 cd34+ stanica/kg tjelesne težine primatelja.

if, for any reason, the patient is unable to receive a scheduled infusion of provenge, the patient will need to undergo an additional leukapheresis procedure if the course of treatment is to be continued.
ako bolesnik iz bilo kojeg razloga ne može primiti predviđenu infuziju lijeka provenge, bit će potrebno ponoviti postupak leukafereze ukoliko se liječenje želi nastaviti.

following randomization, patients from both treatment groups underwent a series of 3 leukapheresis procedures (at approximately 2 week intervals, range 1 to 15 weeks).
nakon randomizacije, bolesnici iz obje skupine ispitanika podvrgnuti su nizu od 3 leukafereze (u intervalima od otprilike 2 tjedna, raspon od 1 do 15 tjedana).

therefore, patient leukapheresis material and provenge may carry the risk of transmitting infectious viruses (hiv 1 and 2, hepatitis b and c) to healthcare professionals handling the product.
stoga, uzorak dobiven leukaferezom i provenge mogu nositi rizik od prenošenja zaraznih virusa (hiv 1 i 2, hepatitisa b i c) na zdravstvene djelatnike koji rukuju lijekom.